Financial Data and Key Metrics Changes - In Q1 2025, the company generated $155 million in net revenue, a 12% increase from the same period last year, driven primarily by an 11% growth in active patients [27] - The gross margin for the quarter was 75%, down from 76% in the prior year, attributed to the rollout of new HFE arrays and the launch of non-small cell lung cancer (NSCLC) treatment [29][30] - The net loss for the quarter was $34 million, with a loss per share of $0.31, and adjusted EBITDA was negative $5 million [33] Business Line Data and Key Metrics Changes - The company reported 4,162 active patients globally for its GBM business, marking a record high and continued year-over-year growth, particularly in France and Japan [21] - For the NSCLC launch, the company received 92 prescriptions in Q1, ending the period with 62 patients on therapy, and had 44 mesothelioma patients on therapy, totaling 106 active patients [13][21] - The company collected $1.5 million from NSCLC claims, split roughly evenly between mesothelioma and NSCLC [28] Market Data and Key Metrics Changes - Active patient growth was 46% in France, 17% in Japan, 10% in Germany, and 4% in the U.S. compared to the prior year [27] - The company anticipates a linear and sustainable adoption curve for its products globally, particularly in the context of the NSCLC launch [20] Company Strategy and Development Direction - The company aims to transition from a single indication treating GBM to a multi-indication oncology company, focusing on execution in regulatory and commercial fronts [8] - The recent CE Mark approval for OptuneLua in Europe for metastatic NSCLC is a significant milestone, with plans for a launch in Germany [9][20] - The company is also preparing for a launch in Japan later this year and is focused on expanding its clinical pipeline to include applications of tumor treating fields in pancreatic and lung cancers [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the technology and the team's ability to reach more patients and drive substantial revenue growth [35] - The company is focused on building a collection track record for NSCLC claims to support revenue recognition upon billing [29] - Management highlighted the importance of the upcoming ASCO presentation for the PANOVA-3 trial, which is expected to generate significant interest in the oncology community [49] Other Important Information - The company is facing potential gross margin headwinds due to evolving tariff landscapes, with estimates indicating that import duties could impact costs significantly [30][75] - The company has initiated several supply chain optimization initiatives to mitigate the impact of tariffs [31] Q&A Session Summary Question: How does the launch of non-small cell lung cancer compare to newly diagnosed GBM? - Management indicated that while it is difficult to directly compare the two, the early adoption metrics for NSCLC are promising, with a focus on the right physicians and patients [40][41] Question: What expectations should be set for the PANOVA-3 presentation at ASCO? - Management confirmed that the presentation will include full data sets and demographic breakdowns, highlighting the trial's success in extending survival in pancreatic cancer [47][48] Question: How is the growth of prescribers expected to evolve? - Management noted that growth will come from both expanding the prescriber base and deepening relationships with current prescribers, with a focus on ensuring quality first experiences [60][62] Question: What is the reimbursement pathway in Germany for NSCLC? - Management explained that reimbursement will initially be on a case-by-case basis, similar to the U.S. market, with expectations for a more predictable reimbursement rate over time [69][70] Question: How is enrollment progressing in the LUNAR trials? - Management stated that enrollment is still in the early stages, with updates expected once there is clearer visibility on patient flow [82]

[Novocure First Quarter 2025 Financial Results Overview](index=1&type=section&id=Novocure%20Reports%20First%20Quarter%202025%20Financial%20Results) [Financial Highlights](index=1&type=section&id=Financial%20updates%20for%20the%20first%20quarter%20ended%20March%2031%2C%202025) Novocure reported **$155 million** in net revenue, a **12% increase**, driven by active patient growth and improved reimbursement, reporting a **$34.3 million** net loss Key Financial Data for Q1 2025 | Metric | Q1 2025 (Million USD) | Q1 2024 (Million USD) | YoY Change | | :--- | :--- | :--- | :--- | | Net Revenue | 155.0 | 138.5 | +12% | | Gross Margin | 75% | 76% | -1% | | Net Loss | (34.3) | (38.8) | -11% | | Adjusted EBITDA | (5.0) | (4.6) | +8% | - Net revenue growth was primarily driven by active patient growth in key markets, followed by improved reimbursement. The U.S., Germany, France, and Japan contributed **$93.2 million**, **$18.7 million**, **$17.9 million**, and **$8.7 million** in revenue, respectively. Greater China, through collaboration with Zai Lab, contributed **$4.6 million**. Optune Lua generated **$1.5 million** in revenue, with **$0.8 million** from MPM and **$0.7 million** from NSCLC[2](index=2&type=chunk) - The decrease in gross margin was primarily due to the rollout of HFE arrays and the launch of the NSCLC product, where the company is treating at-risk on-label patients before widespread reimbursement is established[2](index=2&type=chunk) [Operational and Clinical Highlights](index=2&type=section&id=Operational%20updates%20for%20the%20first%20quarter%20ended%20March%2031%2C%202025) Global active TTFields patients reached **4,268**, with increased operating expenses related to NSCLC launch and future indications, alongside key clinical trial advancements Operating Expenses for Q1 2025 | Expense Category | Q1 2025 (Million USD) | Q1 2024 (Million USD) | YoY Change | | :--- | :--- | :--- | :--- | | Research & Development and Clinical Studies | 53.8 | 51.6 | +4% | | Sales & Marketing | 55.8 | 55.2 | +1% | | General & Administrative | 44.8 | 39.5 | +13% | - As of March 31, 2025, there were **4,268** active TTFields therapy patients globally. Optune Gio prescriptions totaled **1,608**, a **1% year-over-year decrease**, with **4,162** active patients, up **9%**. Optune Lua prescriptions were **127**, including **92** for NSCLC and **35** for MPM, with **106** active patients[6](index=6&type=chunk) - PANOVA-3 Phase III clinical trial results for pancreatic cancer were accepted as a late-breaking abstract for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Optune Lua received CE Mark approval for use in adult patients with metastatic NSCLC in combination with immune checkpoint inhibitors or docetaxel[1](index=1&type=chunk)[12](index=12&type=chunk) [Company Information](index=3&type=section&id=Company%20Information) [About Novocure](index=3&type=section&id=About%20Novocure_details) Novocure is a global oncology company focused on extending survival for aggressive cancer patients through its innovative TTFields therapy - Novocure's mission is to extend the survival of patients with aggressive cancers through Tumor Treating Fields (TTFields) therapy[9](index=9&type=chunk) - Commercialized products are approved for treating glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma, and pleural mesothelioma[9](index=9&type=chunk) - The company's headquarters are in Baar, Switzerland, U.S. headquarters in Portsmouth, New Hampshire, and research facilities in Haifa, Israel[10](index=10&type=chunk) [Detailed Financial Performance](index=5&type=section&id=Detailed%20Financial%20Performance) [Consolidated Statements of Operations](index=5&type=section&id=CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS) Novocure reported **$155 million** in net revenue, a **12% increase**, but incurred an operating loss of **$37.9 million** and a net loss of **$34.3 million** due to increased operating expenses Consolidated Statements of Operations Summary for Q1 2025 | Metric (Thousand USD) | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net Revenue | 154,994 | 138,503 | | Cost of Sales | 38,521 | 33,689 | | Gross Profit | 116,473 | 104,814 | | Research & Development and Clinical Studies Expenses | 53,777 | 51,598 | | Sales & Marketing Expenses | 55,792 | 55,206 | | General & Administrative Expenses | 44,769 | 39,530 | | Operating Loss | (37,865) | (41,520) | | Net Loss | (34,319) | (38,760) | | Basic & Diluted Loss Per Share | (0.31) | (0.36) | [Consolidated Balance Sheets](index=6&type=section&id=Consolidated%20Balance%20Sheets) As of March 31, 2025, Novocure's total assets were **$1.249 billion**, with a decrease in cash offset by an increase in short-term investments, and total liabilities at **$887 million** Consolidated Balance Sheets Summary | Metric (Thousand USD) | March 31, 2025 (Unaudited) | December 31, 2024 (Audited) | | :--- | :--- | :--- | | Cash & Cash Equivalents | 127,279 | 163,767 | | Short-Term Investments | 801,852 | 796,106 | | Accounts Receivable, Net | 84,507 | 74,226 | | Inventory | 39,468 | 35,086 | | Total Current Assets | 1,089,301 | 1,106,575 | | Total Assets | 1,248,809 | 1,240,784 | | Convertible Notes | 558,970 | 558,160 | | Total Current Liabilities | 743,305 | 756,376 | | Total Liabilities | 886,851 | 880,605 | | Total Stockholders' Equity | 361,958 | 360,179 | [Non-GAAP Financial Measures Reconciliation](index=8&type=section&id=Non-U.S.%20GAAP%20financial%20measures%20reconciliation) Novocure's adjusted EBITDA for Q1 2025 was negative **$5.0 million**, an expanded loss compared to Q1 2024, reflecting operational performance excluding certain non-cash items Non-GAAP Financial Measures Reconciliation Summary | Metric (Thousand USD) | Q1 2025 | Q1 2024 | YoY Change | | :--- | :--- | :--- | :--- | | Net Loss | (34,319) | (38,760) | (11)% | | Add: Income Tax Expense | 4,024 | 7,118 | (43)% | | Add: Interest Expense (Income), Net | (7,570) | (9,878) | (23)% | | Add: Depreciation & Amortization | 3,325 | 2,815 | 18% | | EBITDA | (34,540) | (38,705) | (11)% | | Add: Share-Based Compensation | 29,552 | 34,084 | (13)% | | Adjusted EBITDA | (4,988) | (4,621) | 8% | - Adjusted EBITDA is considered a useful metric for evaluating the company's operating performance as it excludes the impact of capital structure, tax rates, and non-cash items, particularly share-based compensation[13](index=13&type=chunk) [Operational Metrics](index=2&type=section&id=Operational%20Metrics) [Key Operating Statistics](index=2&type=section&id=Quarterly%20updates%20and%20achievements_operating_stats) Global active TTFields patients reached **4,268**, with Optune Gio active patients increasing and Optune Lua showing continued growth, while the company plans to shift reporting focus to active patients by indication from Q1 2026 Key Operating Data for Optune Gio and Optune Lua | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Global Active TTFields Patients | 4,268 | 3,845 | | Optune Gio Prescriptions | 1,608 | 1,624 | | Optune Gio Active Patients | 4,162 | 3,819 | | Optune Lua Total Prescriptions | 127 | N/A | | Optune Lua NSCLC Prescriptions | 92 | N/A | | Optune Lua MPM Prescriptions | 35 | N/A | | Optune Lua Active Patients | 106 | 26 | - Starting Q1 2026, Novocure plans to discontinue reporting new prescriptions received during the period, instead focusing on active TTFields therapy patients segmented by indication and key market as key operating statistics[6](index=6&type=chunk) [Active Patients on Therapy](index=8&type=section&id=Active%20Patients%20on%20Therapy) As of March 31, 2025, global active TTFields patients totaled **4,268**, with significant growth in lung cancer indications, reaching **106** patients Active Patients as of March 31, 2025 (by Region and Indication) | Region | CNS (2025) | Lung Cancer (2025) | Total (2025) | CNS (2024) | Lung Cancer (2024) | Total (2024) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | U.S. | 2,157 | 74 | 2,231 | 2,122 | 15 | 2,137 | | Germany | 573 | 21 | 594 | 531 | 9 | 540 | | France | 463 | — | 463 | 318 | — | 318 | | Japan | 445 | — | 445 | 379 | — | 379 | | Other International | 524 | 11 | 535 | 469 | 2 | 471 | | **Global Total** | **4,162** | **106** | **4,268** | **3,819** | **26** | **3,845** | - Lung cancer patients include NSCLC and MPM. As of March 31, 2025, there were **44** active MPM patients and **62** active NSCLC patients globally[19](index=19&type=chunk) [Clinical Development and Regulatory Status](index=1&type=section&id=Clinical%20Development%20and%20Regulatory%20Status) [Recent Clinical and Regulatory Achievements](index=1&type=section&id=Recent%20Clinical%20and%20Regulatory%20Achievements) Novocure achieved significant clinical and regulatory milestones, including PANOVA-3 trial results accepted by ASCO and Optune Lua receiving CE Mark approval for mNSCLC - PANOVA-3 Phase III clinical trial results for pancreatic cancer were accepted as a late-breaking abstract for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting[1](index=1&type=chunk) - Optune Lua received CE Mark approval for use in adult patients with metastatic NSCLC in combination with immune checkpoint inhibitors or docetaxel, following disease progression on platinum-based therapy[1](index=1&type=chunk) [Anticipated Clinical Milestones](index=3&type=section&id=Anticipated%20clinical%20milestones) The company anticipates future data releases for key clinical trials, including PANOVA-4 for metastatic pancreatic cancer and TRIDENT for newly diagnosed glioblastoma - PANOVA-4 Phase II clinical trial data for metastatic pancreatic cancer is anticipated in the first half of 2026[12](index=12&type=chunk) - TRIDENT Phase III clinical trial data for newly diagnosed glioblastoma is anticipated in the first half of 2026[12](index=12&type=chunk) [Risk Factors and Disclosures](index=1&type=section&id=Risk%20Factors%20and%20Disclosures) [Tariff Environment Impact](index=1&type=section&id=Tariff%20Environment%20Impact) The evolving global tariff environment could lead to **$8 million** to **$11 million** in increased import duties for Novocure in 2025, depending on the duration of current tariff suspensions - On April 9, 2025, the U.S. temporarily postponed the implementation of new tariffs for **90 days**, resulting in a **10%** tariff applicable to most countries[2](index=2&type=chunk) - If the current suspension is extended until year-end, Novocure could face up to **$8 million** in increased import tariffs in 2025[2](index=2&type=chunk) - If tariffs revert to pre-April 9 levels after the **90-day** suspension, Novocure could face up to **$11 million** in increased import tariffs in 2025[2](index=2&type=chunk)[3](index=3&type=chunk) [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) This press release contains forward-looking statements regarding future events, subject to inherent risks and uncertainties that may cause actual results to differ materially - Forward-looking statements involve expectations or predictions about future events, including scientific progress, clinical trials, product development, regulatory approvals, manufacturing capabilities, and market outlook[14](index=14&type=chunk) - The company's performance and financial results may differ materially from forward-looking statements due to general financial, economic, environmental, regulatory, and political conditions, and other specific risks and uncertainties[14](index=14&type=chunk) - The company undertakes no obligation to publicly update any forward-looking statements unless required by law[14](index=14&type=chunk) [Important Safety Information](index=9&type=section&id=Product%20Safety%20Information) [Optune Gio Safety Information](index=9&type=section&id=What%20is%20Optune%20Gio%20%C2%AE%20approved%20to%20treat%3F) Optune Gio is an FDA-approved wearable device for adult glioblastoma patients, used with or without temozolomide, with common side effects and contraindications for certain medical conditions - Optune Gio is approved for treating glioblastoma (GBM) in adult patients aged **22** and older[21](index=21&type=chunk) - Contraindications include implanted medical devices, skull defects or shrapnel, and known sensitivity to conductive hydrogels. It should not be used by pregnant women or those planning to become pregnant[23](index=23&type=chunk)[22](index=22&type=chunk) - Common side effects include low platelet count, nausea, constipation, vomiting, fatigue, scalp irritation, headache, seizures, and depression[25](index=25&type=chunk) [Optune Lua Safety Information](index=10&type=section&id=What%20is%20Optune%20Lua%20%C2%AE%20approved%20to%20treat%3F) Optune Lua is an FDA-approved wearable device for adult metastatic NSCLC patients, used in combination with PD-1/PD-L1 inhibitors or docetaxel, with specific contraindications and common side effects - Optune Lua is approved for use in adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on platinum-based therapy, in combination with PD-1/PD-L1 inhibitors or docetaxel[26](index=26&type=chunk) - Contraindications include electrical implants and known sensitivity to the gel. It should not be used by pregnant women or those planning to become pregnant[27](index=27&type=chunk) - Common side effects include dermatitis, musculoskeletal pain, fatigue, anemia, alopecia, dyspnea, nausea, cough, diarrhea, decreased appetite, pruritus, leukopenia, pneumonia, respiratory tract infection, localized edema, rash, pain, constipation, and skin ulceration[28](index=28&type=chunk) [Corporate Communications](index=3&type=section&id=Corporate%20Communications) [Conference Call and Webcast Details](index=3&type=section&id=Conference%20call%20details) Novocure hosted a conference call and webcast on April 24, 2025, to discuss Q1 2025 financial results, with details available on the investor relations page - Novocure hosted a conference call and webcast on Wednesday, April 24, 2025, at **8:00 AM ET**, to discuss its first-quarter 2025 financial results[7](index=7&type=chunk) - The webcast, earnings slides, and company presentation are available on Novocure's investor relations page and will remain accessible for at least **14 days** after the event[8](index=8&type=chunk) [Investor and Media Contacts](index=8&type=section&id=Investors) This report provides detailed contact information for Novocure's investor relations and media inquiries to facilitate stakeholder communication - Investor Contact: Ingrid Goldberg, Email: investorinfo@novocure.com[20](index=20&type=chunk) - Media Contact: Catherine Falcetti, Email: media@novocure.com[20](index=20&type=chunk)

Financial Performance - For the three months ended March 31, 2025, the company's net revenues were $155.0 million, compared to $138.5 million for the same period in 2024, representing a year-over-year increase of approximately 11.5%[83][93] - The net loss for the three months ended March 31, 2025, was $34.3 million, a slight improvement from a net loss of $38.8 million in the same period of 2024[83][93] - The company reported a gross profit of $116.5 million for the three months ended March 31, 2025, up from $104.8 million in the prior year, indicating a gross margin improvement[93] - Net revenues increased by 12% to $155.0 million for the three months ended March 31, 2025, compared to $138.5 million for the same period in 2024, driven by an 11% growth in active patients and reimbursement improvements[98] - Gross margin decreased to 75% for the three months ended March 31, 2025, down from 76% in the same period in 2024, impacted by increased costs and the completion of Zai upfront license recognition[101] - Total operating expenses rose by 5% to $154.3 million, with research and development expenses increasing by 4% to $53.8 million due to ramp-up of clinical trials[103] - Adjusted EBITDA decreased by 8% to $(5.0) million for the three months ended March 31, 2025, primarily driven by increased operating expenses despite revenue growth[108] - Net cash used in operating activities increased by 13% to $(35.7) million for the three months ended March 31, 2025, compared to $(31.6) million in the same period in 2024[111] - Cash, cash equivalents, and short-term investments totaled $929.1 million as of March 31, 2025, a decrease of $30.7 million from $959.9 million at December 31, 2024[110] - Financial income decreased by 23% to $7.6 million for the three months ended March 31, 2025, primarily due to higher interest expenses related to the senior secured credit facility[105] - Income taxes decreased by 43% to $4.0 million for the three months ended March 31, 2025, driven by increased tax benefits from share-based compensation deductions[105] - Net cash provided by financing activities was $5.2 million for the three months ended March 31, 2025, compared to $0.2 million for the same period in 2024[115] Clinical Trials and Product Development - The Phase 3 METIS trial demonstrated a statistically significant improvement in time to intracranial progression for patients treated with TTFields therapy compared to supportive care alone[76][78] - The Phase 3 PANOVA-3 trial showed a statistically significant improvement in overall survival for patients treated with TTFields therapy in combination with gemcitabine and nab-paclitaxel[77][78] - The company anticipates submitting marketing applications to regulators based on the results of the METIS and PANOVA-3 trials[78] Patient Metrics - The number of active patients on therapy is a key revenue driver, with prescriptions received serving as a leading indicator of demand for Optune Gio and Optune Lua[94] - Active patients at period end reached 4,268, with 2,231 in the United States and 2,037 in international markets, reflecting a growth from 3,845 in the previous year[96] Costs and Expenses - Cost of revenues increased by 14% to $38.5 million for the three months ended March 31, 2025, primarily due to an 11% growth in active patients and higher average array costs[99] Debt and Financing - A new five-year senior secured credit facility of up to $400.0 million was entered into on May 1, 2024, with an initial term loan of $100.0 million funded on the same date[119] - The company has the option to draw an additional $100.0 million (Tranche C Loan) if trailing net revenues exceed $575.0 million or if positive results are received from the PANOVA-3 phase 3 clinical trial[120] - The company can draw another $100.0 million (Tranche D Loan) if trailing net revenues exceed $625.0 million or if FDA approval is received for its Tumor Treating Fields device for pancreatic cancer[120] - The outstanding term loans under the Loan Agreement will bear interest at an annual rate of 6.25% plus the three-month SOFR, with a 3.25% floor[120] - The company irrevocably elected to settle all conversions of Notes by a combination of cash and ordinary shares, with cash up to $1,000 per $1,000 principal amount of Notes[117] - The initial conversion rate of the convertible notes is 5.9439 ordinary shares per $1,000 principal amount, equivalent to approximately $168.24 per ordinary share[116] - The company is required to maintain at least $500.0 million in trailing four quarters of net revenue if Tranche C and/or Tranche D Loans are funded[120] Regulatory and Market Conditions - The U.S. increased tariff rates on imported goods, which could potentially increase import duties by up to $11 million in 2025 if tariffs return to pre-April rates[86][87] - The company is actively pursuing contracts with payers to expand access to Optune Lua for patients with NSCLC and MPM[74] Other Financial Information - The company has an accumulated deficit of $1,188.4 million as of March 31, 2025[83] - There have been no material changes in contractual obligations and commitments from the information disclosed in the 2024 10-K[121] - The company currently has no off-balance sheet arrangements as defined under SEC rules[122]

Core Viewpoint - NovoCure's stock price target was cut, leading to a nearly 5% decline in its stock, underperforming compared to the S&P 500 index [1][2] Group 1: Analyst Insights - Wedbush analyst David Nierengarten reduced NovoCure's price target from $29 to $27 per share, maintaining a neutral recommendation [2] - The reasons for the price target reduction were not immediately clear, contributing to bearish sentiment around the stock [2] Group 2: Financial Performance - NovoCure reported a revenue growth of nearly 21% year over year in Q4 2024, exceeding $161 million [3] - The company also experienced a significant net loss of $0.61 per share, which was worse than average analyst estimates [3] Group 3: Market Sentiment - The market is showing impatience for positive news from NovoCure, which is a biotech company requiring time and resources to develop its products [4] - Despite current challenges, the company is considered well-positioned in the cancer treatment segment, suggesting it may be a buy for patient investors [4]

Our Purpose: To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation. ...

Core Insights - Michael Dion is an expert in FP&A, Corporate Finance, and Small Business with 12 years of experience in Fortune 100 companies and various industries [1] - He founded F9 Finance to assist finance professionals and small business owners in understanding finance and accounting concepts [1] - Dion's investment strategy focuses on identifying value opportunities where market reactions to news are disproportionate, emphasizing strong fundamentals and dividends [1] Industry Insights - The finance and accounting sectors are increasingly recognizing the importance of cash flow for both companies and investors [1] - There is a growing trend of small businesses seeking guidance from experienced finance professionals to enhance their financial management [1]

After working as a Registered Nurse for several years, I transitioned into financial analysis, earning my MBA and developing expertise in healthcare & technology investments. Since 2017, I've published investment analyses on Seeking Alpha, focusing on thorough valuation modeling. My approach centers on examining core assumptions that drive stock valuations, particularly through detailed discounted cash flow analysis. I provide readers with various scenarios to help them understand potential outcomes. The pr ...

NovoCure (NVCR) reported $161.27 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 20.6%. EPS of -$0.61 for the same period compares to -$0.45 a year ago.The reported revenue represents a surprise of -0.02% over the Zacks Consensus Estimate of $161.3 million. With the consensus EPS estimate being -$0.34, the EPS surprise was -79.41%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to dete ...

NovoCure (NVCR) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -79.41%. A quarter ago, it was expected that this oncology drug developer would post a loss of $0.34 per share when it actually produced a loss of $0.28, delivering a surprise of 17.65%.Over the last four quarters, the company ha ...

Company Overview - NovoCure Limited held its Q4 2024 Earnings Conference Call on February 27, 2025, at 8:00 AM ET, featuring key executives including Chairman Bill Doyle, CEO Ashley Cordova, and CFO Christoph Brackmann [1][3]. Conference Call Structure - The conference call began with an introduction by Ingrid Goldberg, who welcomed participants and outlined the agenda, which included a presentation followed by a question-and-answer session [2][3]. Financial Performance - The call aimed to review NovoCure's fourth quarter and full year 2024 performance, with accompanying slides available on the company's Investor Relations page [3].